Loading
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Latest quote
$24.41
+$0.58 · +2.43%
After-hours
$24.41
$0.00 · 0.00%
Oct 9, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Day range
Current $24.41
52-week range
Current $24.41
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
24
Expensive
Sentiment
65
Bullish
Risk
43
Elevated Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Day range
Current $24.41
52-week range
Current $24.41
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 247M USD | 258M USD | 117M USD | 112M USD | 383M USD |
| Cost of goods sold | 10M USD | — | — | — | — |
| Gross profit | 237M USD | 258M USD | 117M USD | 112M USD | 383M USD |
| Research and development | 523M USD | 448M USD | 340M USD | 288M USD | 257M USD |
| Selling, general, and administrative | 110M USD | 120M USD | 117M USD | 104M USD | 72M USD |
| Operating expenses | 623M USD | 588M USD | 457M USD | 392M USD | 329M USD |
| Interest income | 41M USD | 52M USD | 41M USD | 16M USD | 1M USD |
| Interest expense | 8M USD | 4M USD | 2M USD | 2M USD | — |
| Depreciation and amortization | 10M USD | 10M USD | 8M USD | 6M USD | 4M USD |
| Operating income | −386M USD | −330M USD | −340M USD | −280M USD | 54M USD |
| Net income | −353M USD | −283M USD | −307M USD | −267M USD | 53M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI82.2M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM56.33M0.07%78.18B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI51.2M0.51%10.11B USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap ETFVB29.63M0.02%185.3B USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF29.49M0.03%95.4B USD0.05%$235+0.80%
Invesco S&P SmallCap Momentum ETFXSMO21.39M0.75%2.87B USD0.35%$81.75+0.57%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM19.72M0.12%15.8B USD0.03%$53.45+0.17%
Vanguard Morningstar Small-Cap Growth ETFVBK16.98M0.04%44.7B USD0.05%$344.74+1.22%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFInvesco S&P SmallCap Momentum ETFXSMOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMVanguard Morningstar Small-Cap Growth ETFVBKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
